- Home
- RARE vs KALU Comparison
RARE vs KALU Comparison
Compare RARE & KALU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RARE | KALU |
|---|---|---|
| Founded | 2010 | 1946 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 2013 | 2006 |
Fundamental Metrics
Financial Performance| Metric | RARE | KALU |
|---|---|---|
| Price | $21.26 | $122.07 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 3 |
| Target Price | $66.32 | ★ $107.00 |
| AVG Volume (30 Days) | ★ 2.0M | 218.6K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 2.45% |
| EPS Growth | 7.31 | ★ 135.89 |
| EPS | N/A | ★ 6.77 |
| Revenue | $673,000,000.00 | ★ $1,585,900,000.00 |
| Revenue This Year | $13.40 | $18.71 |
| Revenue Next Year | $42.83 | $1.97 |
| P/E Ratio | ★ N/A | $18.65 |
| Revenue Growth | ★ 20.13 | N/A |
| 52 Week Low | $18.41 | $46.81 |
| 52 Week High | $40.54 | $150.00 |
Technical Indicators
Market Signals| Indicator | RARE | KALU |
|---|---|---|
| Relative Strength Index (RSI) | 37.40 | 40.62 |
| Support Level | $19.61 | $116.89 |
| Resistance Level | $25.46 | $135.48 |
| Average True Range (ATR) | 0.98 | 6.95 |
| MACD | 0.03 | -1.55 |
| Stochastic Oscillator | 39.06 | 16.91 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About KALU Kaiser Aluminum Corporation
Kaiser Aluminum Corp produces and sells semi-fabricated specialty aluminum products predominantly to industrial customers. Its products include fabricated aluminum mill products such as flat-rolled (plate, sheet, and coil), extruded (rod, bar, hollows, and shapes), drawn (rod, bar, pipe, tube and wire) and certain cast aluminum products. Geographically, the company generates majority of its revenue from the United States.